3D texture analysis reveals imperceptible MRI textural alterations in the thalamus and putamen in progressive myoclonic epilepsy type 1, EPM1

PLoS One. 2013 Jul 29;8(7):e69905. doi: 10.1371/journal.pone.0069905. Print 2013.

Abstract

Progressive myoclonic epilepsy type 1 (EPM1) is an autosomal recessively inherited neurodegenerative disorder characterized by young onset age, myoclonus and tonic-clonic epileptic seizures. At the time of diagnosis, the visual assessment of the brain MRI is usually normal, with no major changes found later. Therefore, we utilized texture analysis (TA) to characterize and classify the underlying properties of the affected brain tissue by means of 3D texture features. Sixteen genetically verified patients with EPM1 and 16 healthy controls were included in the study. TA was performed upon 3D volumes of interest that were placed bilaterally in the thalamus, amygdala, hippocampus, caudate nucleus and putamen. Compared to the healthy controls, EPM1 patients had significant textural differences especially in the thalamus and right putamen. The most significantly differing texture features included parameters that measure the complexity and heterogeneity of the tissue, such as the co-occurrence matrix-based entropy and angular second moment, and also the run-length matrix-based parameters of gray-level non-uniformity, short run emphasis and long run emphasis. This study demonstrates the usability of 3D TA for extracting additional information from MR images. Textural alterations which suggest complex, coarse and heterogeneous appearance were found bilaterally in the thalamus, supporting the previous literature on thalamic pathology in EPM1. The observed putamenal involvement is a novel finding. Our results encourage further studies on the clinical applications, feasibility, reproducibility and reliability of 3D TA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Female
  • Humans
  • Magnetic Resonance Imaging / methods*
  • Male
  • Myoclonic Epilepsies, Progressive / pathology*
  • Putamen / pathology*
  • Thalamus / pathology*
  • Young Adult

Grants and funding

This work was partially supported by EVO grants 5772751 and 5063523 from Kuopio University Hospital (SS), Strategic Funding for the UEF-BRAIN consortium from University of Eastern Finland (SS), Finnish Brain Foundation (SS), Neuroradiologists of Finland (SS), Instrumentarium Research Foundation (SS), Academy of Finland (RK) and UCB Pharma (RK). Outside the submitted work RK has received funding for travel from UCB Pharma and Eisai; and has received speaker honoraria from UCB Pharma, Eisai, Orion, Pfizer and GlaxoSmithKline. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.